Strategic insight and execution support to maximize biotech investment outcomes
Alacrita partners with venture firms to strengthen investment decisions and support portfolio company execution. Whether evaluating an opportunity, supporting the formation of a new biotech, or helping a team deliver on key development milestones, we provide flexible, high-caliber consulting across core functions. Our work complements internal capabilities, helping companies operate with greater speed, clarity, and confidence.
Investment Readiness & Opportunity Assessment
Alacrita partners with venture firms to enhance diligence, accelerate evaluation, and bring clarity to complex life science investments. Whether supporting established funds or newer tech-focused investors entering the sector as biology and technology converge at new intersections, we provide real-world development insight and commercial context that complement internal capabilities.
- Technical due diligence on assets, platforms, and scientific rationale
- Commercial and strategic assessments, including TPP development, indication prioritization, and market opportunity modeling
- Competitive landscape and CI analysis to guide positioning and differentiation
- Valuation modeling and scenario planning to inform deal structures and exit strategies
- Development gap analysis across clinical, regulatory, CMC, and operational readiness
- Identification and placement of interim leaders, including CSO, CMO, and regulatory experts
- Assessments of pharma partnering potential, strategic fit, and differentiation
- Packaging and communication of opportunities, including investor materials, pitch decks, and data room content
- Narrative refinement focused on unmet need, scientific rationale, and value clarity
- Evaluation of academic spinouts, incubator-stage ventures, and emerging platforms
- Assessment of founding science, IP positioning, and investability
Post-Investment Execution Support
If your portfolio companies require operational support post-investment, Alacrita can serve as a trusted and flexible partner. We can work directly with company management teams to provide targeted expertise across critical development functions, complement internal resources, and help deliver on key milestones.
- Strategic guidance to support asset acquisition or maximize internal portfolios through focused IP due diligence
- Scientific, technical, and regulatory input for early-stage development and program planning
- Support from experienced drug development physicians and clinical operations consultants to shape and drive trial strategy
- Deep knowledge of US and EU regulatory frameworks, filings, and agency interactions to de-risk development
- Integrated support across pharmaceutical development, quality, CMC-regulatory, and supply chain planning
- Placement of interim CMOs and other functional leads to bridge execution gaps or supplement early management teams
Virtual & Semi-Virtual Biotech Enablement
For those launching new biotech ventures without fully built internal teams, Alacrita offers a flexible operating model that provides execution support across major core functions. Our team integrates seamlessly into early-stage companies to guide strategy, manage progress, and deliver on development priorities.
- Acting as interim CSO, CMO, regulatory lead, or clinical program lead
- Supporting decision-making at the management and board level
- Across key functions including preclinical, clinical, regulatory, and CMC
- Focused on milestone clarity, risk mitigation, and capital-efficient execution
- 350+ specialists across therapeutic areas and development stages
- Curated and deployed based on the specific needs of the company
- Shaping strategy, positioning, and scientific narrative
- Contributing to pitch materials, data rooms, and external-facing communications
- Flexible model tailored to company maturity and development priorities
- Suitable for academic spinouts, emerging platform companies, or biotechs with near-term partnering objectives